Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.2052W HIGH $37.48
Volume
550.06 K
Value Traded
11.76 M
Short % Float
13.11%
Days to Cover
6.5
-3.11%Week
-17.07%1 Month
-20.67%3 Month
-8.9%6 Month
-3.55%5 Year
-3.55%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
867.64 M
EPS (TTM)
-2.15
P/E Ratio
-
Ent. Value
642.56 M
Total Shares
39.24 M
Float Shares
35.55 M
Insiders
9.40%
Institutions
79.59%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ANRO Catalyst Timeline
Dated clinical, regulatory and corporate events for Alto Neuroscience, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alto Neuroscience, Inc.
143Total events
16Upcoming
50Tier-1 (high impact)
2023 to 2040Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Pricing of $100.0 million underwritten registered direct offering of common stock
▲Timing GuidanceALTO-207Presentation
Alto announced plans to accelerate and expand ALTO-207 development including additional Phase 3 monotherapy trial
treatment-resistant depression (monotherapy)source ↗
▼Equity OfferingCorporate
Completed underwritten registered direct offering of ~$100.0 million
▲PublicationpramipexolePresentation
Nature Medicine publication demonstrating significant effects of Pramipexole on anhedonia
anhedoniasource ↗
◆Topline ReadoutALTO-300Clinical Data
Topline data for ALTO-300 Phase 2b MDD trial
major depressive disordersource ↗
▲PublicationpramipexolePresentation
PRIME-PRAXOL results published in Nature Medicine
major depressive disorder, dysthymia, or bipolar depression with clinically significant anhedoniasource ↗
▲Primary Endpoint MetpramipexoleClinical Data
PRIME-PRAXOL met primary endpoint (SHAPS, p=0.006)
major depressive disorder, dysthymia, or bipolar depression with clinically significant anhedoniasource ↗
▲Poster PresentationALTO-207Presentation
Phase 2a data for ALTO-207 presented at SOBP Annual Meeting
Major Depressive Disordersource ↗
▲Trial InitiationALTO-207Trial
Initiation of Phase 2b trial of ALTO-207 in TRD
treatment-resistant depressionsource ↗
▼Topline ReadoutALTO-101Clinical Data
ALTO-101 Phase 2 POC trial topline results reported
cognitive impairment associated with schizophrenia (CIAS)source ↗
▲Trial InitiationALTO-207Trial
Phase 2b trial of ALTO-207 in TRD initiated
treatment-resistant depression (TRD)source ↗
▼Program DiscontinuationALTO-101Corporate
Alto discontinues independent development of ALTO-101 in CIAS
cognitive impairment associated with schizophreniasource ↗
◆Topline ReadoutALTO-300Clinical Data
Topline results expected in mid-2026
major depressive disordersource ↗
◆Oral PresentationPresentation
Alto Neuroscience management to participate in virtual fireside chat at Stifel 2026 Virtual CNS Forum
▲Enrollment CompleteALTO-101Trial
Completion of patient enrollment in Phase 2 proof-of-concept study of ALTO-101 in CIAS
cognitive impairment associated with schizophreniasource ↗
●PublicationPresentation
Publication of review 'Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments' in American Journal of Psychiatry
▲Enrollment CompleteALTO-101Trial
Enrollment completed in Phase 2 POC trial of ALTO-101
Cognitive Impairment Associated with Schizophreniasource ↗
▲Patent GrantedALTO-207IP / Competition
Issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207
depressionsource ↗
▲Patent GrantedALTO-207IP / Competition
Issuance of U.S. Patent No. 12,521,374 covering methods of treating depression with ALTO-207
depressionsource ↗
◆Oral PresentationALTO-203Presentation
Prospective replication of an EEG biomarker for predicting changes in attention with ALTO-203
cognitive impairment associated with schizophreniasource ↗
◆Oral PresentationPresentation
Event-Related Theta Responses as Candidate Markers of Cognitive Impairment Associated with Schizophrenia: Independent Replication of Case-Control Differences and Cognitive Associations in a Large Patient Sample
schizophreniasource ↗
●Poster PresentationPresentation
Poster presentation on Event-Related Theta Responses as Candidate Markers of CIAS at ACNP 2026
Cognitive Impairment Associated with Schizophreniasource ↗
●Poster PresentationALTO-203Presentation
Poster presentation on prospective replication of EEG biomarker for predicting changes in attention with ALTO-203 at ACNP 2026
Excessive daytime sleepiness and/or deficits in sustained attentionsource ↗
◆Topline ReadoutALTO-101Clinical Data
Topline data from ALTO-101 POC trial
Cognitive Impairment Associated with Schizophreniasource ↗
◆Trial InitiationALTO-207Trial
Initiate Phase 2b study of ALTO-207 in TRD
treatment resistant depressionsource ↗
▲Patent GrantedALTO-207IP / Competition
U.S. Patent No. 12,521,374 issued for ALTO-207
treatment-resistant depression (TRD)source ↗
▲FDA Feedback ReceivedALTO-207FDA Meeting
Successful FDA meeting regarding development path of ALTO-207
treatment resistant depressionsource ↗
▲Fast Track DesignationALTO-101Designation
FDA Fast Track Designation for ALTO-101
Cognitive Impairment Associated with Schizophreniasource ↗
▲FDA Feedback ReceivedALTO-207FDA Meeting
Successful outcome from FDA meeting for ALTO-207
treatment-resistant depressionsource ↗
▲PK PD DataALTO-101Clinical Data
Positive blinded PK analysis from first cohort of ALTO-101 Phase 2 trial
cognitive impairment in schizophreniasource ↗
▲PK PD DataALTO-100Clinical Data
Positive blinded PK analysis from first cohort of ALTO-100 Phase 2b trial
bipolar depressionsource ↗
◆Topline ReadoutALTO-101Clinical Data
Topline data from Phase 2 proof-of-concept CIAS trial of ALTO-101
Cognitive Impairment Associated with Schizophreniasource ↗
◆Quarterly UpdateCorporate
Lead plaintiff filing deadline for securities class action lawsuit
●Oral PresentationPresentation
TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry Epilepsy Summit
▲PublicationPresentation
PAX-D study results published in The Lancet Psychiatry
treatment resistant depressionsource ↗
Past FDA Catalysts and PDUFA Decisions
How ANRO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | ALTO-101 | Phase 2a data readout | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
5
Drugs Scored
rNPV / MCap
Top Drug
Top 26%
Micro Cap(rank 172 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALTO-100 Small moleculeNCT06656416 | Bipolar Disorder I or II With a Major Depressive Episode | Phase 2 | RECRUITING | 200 | Oct 1, 2027 | ||||||
| ALTO-101 Small moleculeNCT06502964 | Schizophrenia | Phase 2 | RECRUITING | 82 | Mar 1, 2026 | ||||||
| ALTO-207 Small moleculeNCT07553637 | Treatment-resistant Depression (TRD) | Phase 2 | RECRUITING | 178 | Dec 1, 2027 | ||||||
| ALTO-300 Small moleculeNCT05157945 | Major Depressive Disorder | Phase 2 | COMPLETED | 560 | May 5, 2023 | ||||||
| ALTO-203 25 μg Small moleculeCompletedNCT06391593 | Major Depressive Disorder | Phase 2 | COMPLETED | 69 | Apr 21, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every ANRO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ALTO-207 | Major Depressive Disorder | Phase 2a | 2026-05-04 | ALTO-207 met primary and secondary endpoints demonstrating significantly greater improvements on MADRS compared to placebo. Patients randomized to receive ALTO-207 reached a mean dose of 4.1mg per day.Read More | Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Smith Nicholas ConradOfficer (PRESIDENT AND CFO) | Option | 55,000 79,060 held | $2.32 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ANRO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| COMMODORE CAPITAL LP | 4.3 % (22.9 %) | 71.87 M | 2.72 M |
ANRO Institutional Ownership Trends
ANRO Short Interest
Shares sold short, counted twice a month.
13.11%
Short % of Float
of tradable shares sold short
4.7M
Shares Sold Short
+11.6% vs prior count
6.5 High
Days to Cover
trading days of normal volume to buy every short share back
718.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ANRO ranks across every disease it competes in
Competitive Position is a premium feature
See how ANRO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialANRO News
ANROAlto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience, a clinical-stage biopharmaceutical company, has announced its participation in upcoming investor conferences, including the H.C. Wainwright 28th Annual Global Healthcare Conference. The management team will engage in a fireside chat and one-on-one meetings, highlighting the company's focus on developing precision medicines for neuropsychiatric disorders.
Read more →ANROAlto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Alto Neuroscience has announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. In his new role, Smith will lead the finance function and oversee corporate strategy and business development. This move is part of the company's efforts to enhance its leadership as it develops novel treatments for neuropsychiatric disorders.
Read more →ANRO▲ +10.7%on this news
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience, a clinical-stage biopharmaceutical company, has reported its financial results for the second quarter of 2026. The report emphasizes the progress made in its pipeline, particularly regarding the product candidate ALTO-207. The company expresses strong confidence in the opportunities that lie ahead.
Read more →ANRO▲ +5.9%on this news
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Alto Neuroscience has announced the pricing of a registered direct offering of 3,776,436 shares of common stock at $26.48 per share. This offering aims to raise $100 million in gross proceeds, which will support the company's mission to develop personalized psychiatric treatments. The entire offering is being conducted by Alto Neuroscience.
Read more →ANROAlto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
Alto Neuroscience has highlighted a publication in Nature Medicine regarding the effects of Pramipexole on anhedonia. The article suggests that the drug may have significant impacts on this condition. However, further details about the findings or implications are not provided in the text.
Read more →ANROAlto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
Alto Neuroscience has appointed Andrew Miller, Ph.D., the founder of Karuna Therapeutics, to its Board of Directors. This strategic move is expected to enhance the company's leadership and expertise in neuroscience. Further details regarding Miller's role and contributions have not been disclosed.
Read more →ANROAlto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
Amit Etkin, CEO of Alto Neuroscience, received the Transformational Research Award from Columbia University for his contributions to neuropsychiatric research. The award recognizes alumni making significant impacts in biomedical research. Etkin's work focuses on developing personalized treatments for mental health disorders through the Precision Psychiatry Platform, which utilizes brain-based biomarkers.
Read more →ANRO▼ -7.2%on this news
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience has reported its financial results for the first quarter of 2026. The report includes recent business highlights, though specific details are not provided in the article. The overall sentiment remains neutral due to the lack of substantial information regarding performance or developments.
Read more →ANROAlto Neuroscience Announces Participation in Upcoming Investor Conferences - May 11, 2026
Alto Neuroscience, a clinical-stage biopharmaceutical company, has announced its participation in upcoming investor conferences. The management team will present information on their innovative approach to neuropsychiatric disorders and their clinical-stage pipeline. Presentations will be accessible via live webcast and will include discussions on their Precision Psychiatry Platform™.
Read more →ANROAlto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
Alto Neuroscience presented Phase 2a data for ALTO-207 targeting Major Depressive Disorder at the SOBP Annual Meeting. The presentation highlights the company's ongoing research efforts in this area. Further details on the data and its implications were not provided in the article.
Read more →ANRO▼ -6.4%on this news
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
Alto Neuroscience has announced the initiation of a Phase 2b trial for ALTO-207, targeting treatment-resistant depression (TRD). This trial aims to replicate positive results from the PAX-D study and is designed to address tolerability issues associated with pramipexole. Approximately 178 adults will participate, with topline data expected in late 2027.
Read more →ANROAlto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
Alto Neuroscience announced topline data from its Phase 2 trial of ALTO-101 for cognitive impairment associated with schizophrenia. While the study did not meet primary endpoints, it showed some directional improvements in EEG measures. The company plans to focus on its lead program, ALTO-207, which is set to enter a Phase 2b trial in 2026, while exploring partnerships for ALTO-101.
Read more →ANRO▲ +9.1%on this news
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
Alto Neuroscience reported strong financial results for 2025, with a cash balance of $177 million. The company is advancing its pipeline, particularly ALTO-207 for treatment-resistant depression, into a pivotal Phase 2b trial. Positive validation from the PAX-D study supports their approach, although challenges remain due to adverse effects linked to pramipexole.
Read more →ANRO▲ +9.1%on this news
Alto Neuroscience Announces $120 Million Private Placement Financing
Alto Neuroscience has announced a $120 million private placement financing to support the development of ALTO-207, a treatment for treatment resistant depression. The financing, led by Commodore Capital, will fund a planned Phase 3 clinical trial and working capital. The company anticipates initiating a Phase 2b study in early 2026 and a Phase 3 study in early 2027.
Read more →ANROAlto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
Alto Neuroscience announced its participation in the Stifel 2026 Virtual CNS Forum, scheduled for March 17, 2026. The management team will engage in a virtual fireside chat, which will be accessible via a live webcast. Alto is dedicated to developing precision medicines for neuropsychiatric disorders, utilizing advanced neurobiological techniques.
Read more →ANROAlto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
Alto Neuroscience has completed patient enrollment for its Phase 2 proof-of-concept trial of ALTO-101, aimed at treating cognitive impairment associated with schizophrenia. The study involves 83 patients across 13 sites and will assess the drug's effects on EEG measures linked to cognitive dysfunction. Topline data is expected by the end of Q1, which will inform future development decisions.
Read more →ANROAlto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
Alto Neuroscience has published a review in the American Journal of Psychiatry, emphasizing neuroplasticity as a key factor in psychiatric disorders and treatment. The review consolidates evidence that disrupted neuroplasticity is a common biological driver for conditions such as depression and schizophrenia. It advocates for the development of therapies that restore neuroplasticity, highlighting the need for translatable biomarkers to improve treatment outcomes.
Read more →ANROAlto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
Alto Neuroscience has announced the issuance of a new U.S. patent for ALTO-207, a treatment for depression that combines pramipexole and ondansetron. This patent enhances the company's intellectual property portfolio and aims to mitigate side effects associated with pramipexole, allowing for higher dosing. The company believes this positions ALTO-207 as a significant asset in the treatment landscape for patients with treatment-resistant depression.
Read more →ANROAlto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
Alto Neuroscience presented new data at the 64th annual meeting of the ACNP, focusing on their precision psychiatry platform. CEO Amit Etkin expressed excitement about the clinical milestones expected in the year ahead. The presentations included findings on EEG biomarkers related to cognitive impairment and treatment responses in various mental health conditions.
Read more →About Alto Neuroscience, Inc.
Headquarters650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, CA, 94041
BIOPHARMAWATCH ELITE PLUS
Trade the next ANRO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime